The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis
Abstract
Patients with chronic liver disease and cirrhosis demonstrate a global mucosal immune impairment, which is associated with altered gut microbiota composition and functionality. These changes progress along with the advancing degree of cirrhosis and can be linked with hepatic encephalopathy, infections and even prognostication independent of clinical biomarkers. Along with compositional changes, microbial functional alterations focused on short-chain fatty acids, bioenergetics and bile acid metabolism are also associated with cirrhosis progression and outcomes. Altering the microbial functional and structural profile is partly achieved by medications used in patients with cirrhosis such as rifaximin, lactulose, proton pump inhibitors and other antibiotics. However, the role of fecal or intestinal microbiota transplantation is being increasingly recognized. The challenges, opportunities and the road ahead for the appropriate and safe use of intestinal microbiota transplantation in liver disease are reviewed, which opens up an exciting field of investigation and therapy in cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Burden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Gut biogeography of the bacterial microbiota
Donaldson, G. P., Lee, S. M., & Mazmanian, S. K. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro3552 · Cited by 2,535
Alterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
Zmora, N., Zilberman-Schapira, G., Suez, J., Mor, U., Dori-Bachash, M., Bashiardes, S., Kotler, E., Zur, M., Regev-Lehavi, D., Brik, R. B.-Z., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.041 · Cited by 1,695
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910437 · Cited by 1,281
Paramsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276
Altered profile of human gut microbiome is associated with cirrhosis and its complications
Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., White, M. B., Monteith, P., Noble, N. A., Unser, A. B., Daita, K., Fisher, A. R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.019 · Cited by 1,099
Self-citationKootte, R. S., Levin, E., Salojärvi, J., Smits, L. P., Hartstra, A. V., Udayappan, S. D., Hermes, G., Bouter, K. E., Koopen, A. M., Holst, J. J., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.008 · Cited by 1,039
Leclercq, S., Matamoros, S., Cani, P. D., Neyrinck, A. M., Jamar, F., Stärkel, P., Windey, K., Tremaroli, V., Bäckhed, F., Verbeke, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415174111 · Cited by 972
Interactions Between the Intestinal Microbiome and Liver Diseases
Schnabl, B., & Brenner, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.020 · Cited by 971
Colonic microbiome is altered in alcoholism
Mutlu, E. A., Gillevet, P. M., Rangwala, H., Sikaroodi, M., Naqvi, A., Engen, P. A., Kwasny, M., Lau, C. K., & Keshavarzian, A. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00380.2011 · Cited by 775
Gut–Liver Axis in Alcoholic Liver Disease
Szabo, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.042 · Cited by 754
Ott, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.010 · Cited by 695
Khoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c87e02 · Cited by 649
Self-citationLee, C. H., Steiner, T., Petrof, E. O., Smieja, M., Roscoe, D., Nematallah, A., Weese, J. S., Collins, S., Moayyedi, P., Crowther, M., et al. (2016) · JAMA · doi:10.1001/jama.2015.18098 · Cited by 627
Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease
Grander, C., Adolph, T. E., Wieser, V., Lowe, P., Wrzosek, L., Gyongyosi, B., Ward, D. V., Grabherr, F., Gerner, R. R., Pfister, A., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313432 · Cited by 618
Kao, D., Roach, B., Silva, M., Beck, P., Rioux, K., Kaplan, G. G., Chang, H.-J., Coward, S., Goodman, K. J., Xu, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.17077 · Cited by 615
Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31785-9 · Cited by 550
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella Pneumoniae
Yuan, J., Chen, C., Cui, J., Lu, J., Yan, C., Wei, X., Zhao, X., Li, N., Li, S., Xue, G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.018 · Cited by 548
Linkage of gut microbiome with cognition in hepatic encephalopathy
Bajaj, J. S., Ridlon, J. M., Hylemon, P. B., Thacker, L. R., Heuman, D. M., Smith, S., Sikaroodi, M., & Gillevet, P. M. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00190.2011 · Cited by 547
Self-citationMicrobiota and host determinants of behavioural phenotype in maternally separated mice
De Palma, G., Blennerhassett, P., Lu, J., Deng, Y., Park, A. J., Green, W., Denou, E., Silva, M. A., Santacruz, A., Sanz, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms8735 · Cited by 517
Tang, R., Wei, Y., Li, Y., Chen, W., Chen, H., Wang, Q., Yang, F., Miao, Q., Xiao, X., Zhang, H., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313332 · Cited by 434
Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430
Weingarden, A. R., Chen, C., Bobr, A., Yao, D., Lu, Y., Nelson, V. M., Sadowsky, M. J., & Khoruts, A. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00282.2013 · Cited by 423
Self-citationPrimary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD
Sabino, J., Vieira-Silva, S., Machiels, K., Joossens, M., Falony, G., Ballet, V., Ferrante, M., Van Assche, G., Van der Merwe, S., Vermeire, S., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311004 · Cited by 413
Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
Ma, Y.-Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i40.6911 · Cited by 352
Dhiman, R. K., Rana, B., Agrawal, S., Garg, A., Chopra, M., Thumburu, K. K., Khattri, A., Malhotra, S., Duseja, A., & Chawla, Y. K. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.031 · Cited by 339
A Gut Microbiome Signature for Cirrhosis Due to Nonalcoholic Fatty Liver Disease
Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., Bettencourt, R., Rizo, E., Richards, L., Xu, Z. Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09455-9 · Cited by 338
Cirrhosis, bile acids and gut microbiota: Unraveling a complex relationship
Ridlon, J. M., Alves, J. M., Hylemon, P. B., & Bajaj, J. S. (2013) · Gut Microbes · doi:10.4161/gmic.25723 · Cited by 336
Self-citationSalivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy
Bajaj, J. S., Betrapally, N. S., Hylemon, P. B., Heuman, D. M., Daita, K., White, M. B., Unser, A., Thacker, L. R., Sanyal, A. J., Kang, D. J., et al. (2015) · Hepatology · doi:10.1002/hep.27819 · Cited by 325
Self-citationLlorente, C., Jepsen, P., Inamine, T., Wang, L., Bluemel, S., Wang, H. J., Loomba, R., Bajaj, J. S., Schubert, M. L., Sikaroodi, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00796-x · Cited by 257
Self-citationLelouvier, B., Servant, F., Païssé, S., Brunet, A., Benyahya, S., Serino, M., Valle, C., Ortiz, M. R., Puig, J., Courtney, M., et al. (2016) · Hepatology · doi:10.1002/hep.28829 · Cited by 242
Allegretti, J. R., Kassam, Z., Carrellas, M., Mullish, B. H., Marchesi, J. R., Pechlivanis, A., Smith, M., Gerardin, Y., Timberlake, S., Pratt, D. S., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000115 · Cited by 234
Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology
Chen, Y., Ji, F., Guo, J., Shi, D., Fang, D., & Li, L. (2016) · Scientific Reports · doi:10.1038/srep34055 · Cited by 205
Causality of small and large intestinal microbiota in weight regulation and insulin resistance
Scheithauer, T. P. M., Dallinga-Thie, G. M., de Vos, W. M., Nieuwdorp, M., & van Raalte, D. H. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.002 · Cited by 188
Bajaj, J. S., Cox, I. J., Betrapally, N. S., Heuman, D. M., Schubert, M. L., Ratneswaran, M., Hylemon, P. B., White, M. B., Daita, K., Noble, N. A., et al. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00268.2014 · Cited by 143
Self-citationSung, C. M., Lin, Y.-F., Chen, K.-F., Ke, H.-M., Huang, H.-Y., Gong, Y.-N., Tsai, W.-S., You, J.-F., Lu, M. J., Cheng, H.-T., et al. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.008 · Cited by 127
Bajaj, J. S., Idilman, R., Mabudian, L., Hood, M., Fagan, A., Turan, D., White, M. B., Karakaya, F., Wang, J., Atalay, R., et al. (2018) · Hepatology · doi:10.1002/hep.29791 · Cited by 125
Self-citationDecompensated cirrhosis and microbiome interpretation
Bajaj, J. S., Betrapally, N. S., & Gillevet, P. M. (2015) · Nature · doi:10.1038/nature14851 · Cited by 100
Self-citationHCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients
Bajaj, J. S., Sterling, R. K., Betrapally, N. S., Nixon, D. E., Fuchs, M., Daita, K., Heuman, D. M., Sikaroodi, M., Hylemon, P. B., White, M. B., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13732 · Cited by 63
Self-citation
Research works printed but not linked: 140
- Wiest, 2017, Targeting the gut-liver axis in liver disease, J Hepatol, 67, 1084, 10.1016/j.jhep.2017.05.007 · DOI · Paper page
- Allaband, 2019, Microbiome 101: studying, analyzing, and interpreting gut microbiome data for clinicians, Clin Gastroenterol Hepatol, 17, 218, 10.1016/j.cgh.2018.09.017 · DOI · Paper page
- Acharya, 2019, Altered microbiome in patients with cirrhosis and complications, Clin Gastroenterol Hepatol, 17, 307, 10.1016/j.cgh.2018.08.008 · DOI · Paper page
- Asrani, 2019, Burden of liver diseases in the world, J Hepatol, 70, 151, 10.1016/j.jhep.2018.09.014 · DOI · Paper page
- Bajaj, 2019, Alcohol, liver disease and the gut microbiota, Nat Rev Gastroenterol Hepatol, 16, 235, 10.1038/s41575-018-0099-1 · DOI · Paper page
- Hatton, 2019, Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?, Expert Rev Gastroenterol Hepatol, 13, 1, 10.1080/17474124.2019.1543587 · DOI
- Khoruts, 2019, Fecal microbiota transplant: a rose by any other name, Am J Gastroenterol, 114, 1176, 10.14309/ajg.0000000000000286 · DOI
- Yang, 2017, Intestinal fungi contribute to development of alcoholic liver disease, J Clin Invest, 127, 2829, 10.1172/JCI90562 · DOI · Paper page
- Bajaj, 2017, Continued alcohol misuse in human cirrhosis is associated with an impaired gut-liver axis, Alcohol Clin Exp Res, 41, 1857, 10.1111/acer.13498 · DOI
- Llopis, 2016, Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease, Gut, 65, 830, 10.1136/gutjnl-2015-310585 · DOI · Paper page
- Pinzone, 2012, Microbial translocation in chronic liver diseases, Int J Microbiol, 2012, 694629, 10.1155/2012/694629 · DOI
- Young, 2017, The role of the microbiome in human health and disease: an introduction for clinicians, BMJ, 356, j831, 10.1136/bmj.j831 · DOI · Paper page
- Sookoian, 2020, Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease, Gut, 10.1136/gutjnl-2019-318811 · DOI · Paper page
- Hornung, 2019, Response to: ‘Circulating microbiome in blood of different circulatory compartments' by Schierwagen et al, Gut
- Loomba, 2019, Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease, Cell Metab, 30, 607, 10.1016/j.cmet.2019.08.002 · DOI · Paper page
- Wei, 2019, Alterations of gut microbiome in autoimmune hepatitis, Gut, 69, 569, 10.1136/gutjnl-2018-317836 · DOI · Paper page
- Kummen, 2017, The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls, Gut, 66, 611, 10.1136/gutjnl-2015-310500 · DOI · Paper page
- Ruhlemann, 2017, Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis, Gut, 66, 753, 10.1136/gutjnl-2016-312180 · DOI
- Pereira, 2017, Bile microbiota in primary sclerosing cholangitis: impact on disease progression and development of biliary dysplasia, PLoS One, 12, e0182924, 10.1371/journal.pone.0182924 · DOI
- Inoue, 2018, Gut dysbiosis associated with hepatitis C virus infection, Clin Infect Dis, 67, 869, 10.1093/cid/ciy205 · DOI · Paper page
- Preveden, 2017, Gut microbiota changes and chronic hepatitis C virus infection, Expert Rev Gastroenterol Hepatol, 11, 813, 10.1080/17474124.2017.1343663 · DOI
- Heidrich, 2018, Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls, Liver Int, 38, 50, 10.1111/liv.13485 · DOI
- Lu, 2011, Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients, Microb Ecol, 61, 693, 10.1007/s00248-010-9801-8 · DOI · Paper page
- Wei, 2013, Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach, BMC Gastroenterol, 13, 175, 10.1186/1471-230X-13-175 · DOI
- Bajaj, 2019, Gut microbiota as biosensors in patients with cirrhosis, Cell Mol Gastroenterol Hepatol, 8, 231, 10.1016/j.jcmgh.2019.04.016 · DOI
- D'Amico, 2006, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies, J Hepatol, 44, 217, 10.1016/j.jhep.2005.10.013 · DOI · Paper page
- Arvaniti, 2010, Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis, Gastroenterology, 139, 1246, 10.1053/j.gastro.2010.06.019 · DOI · Paper page
- Puri, 2018, The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis, Hepatology, 67, 1284, 10.1002/hep.29623 · DOI
- Duan, 2019, Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease, Nature, 575, 505, 10.1038/s41586-019-1742-x · DOI · Paper page
- Ciocan, 2018, Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis, Aliment Pharmacol Ther, 48, 961, 10.1111/apt.14949 · DOI
- Tandon, 2008, Bacterial infections, sepsis, and multiorgan failure in cirrhosis, Semin Liver Dis, 28, 26, 10.1055/s-2008-1040319 · DOI · Paper page
- Di Lorenzo, 2019, Lipopolysaccharide structures of Gram-negative populations in the gut microbiota and effects on host interactions, FEMS Microbiol Rev, 43, 257, 10.1093/femsre/fuz002 · DOI · Paper page
- Bajaj, 2018, Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis, Am J Gastroenterol, 113, 1177, 10.1038/s41395-018-0085-9 · DOI
- Chen, 2011, Characterization of fecal microbial communities in patients with liver cirrhosis, Hepatology, 54, 562, 10.1002/hep.24423 · DOI · Paper page
- Bajaj, 2012, Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation, Am J Physiol Gastrointest Liver Physiol, 303, G675, 10.1152/ajpgi.00152.2012 · DOI · Paper page
- Bajaj, 2019, Alterations in skin microbiomes of patients with cirrhosis, Clin Gastroenterol Hepatol, 17, 2581, 10.1016/j.cgh.2019.03.028 · DOI
- Vilstrup, 2014, Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver, Hepatology, 60, 715, 10.1002/hep.27210 · DOI · Paper page
- Patidar, 2014, Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization, Am J Gastroenterol, 109, 1757, 10.1038/ajg.2014.264 · DOI · Paper page
- Kang, 2016, Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice, Hepatology, 64, 1232, 10.1002/hep.28696 · DOI
- Sarma, 2011, Multi-dimensional MR spectroscopy: towards a better understanding of hepatic encephalopathy, Metab Brain Dis, 26, 173, 10.1007/s11011-011-9250-1 · DOI
- Ahluwalia, 2016, Impaired gut-liver-brain axis in patients with cirrhosis, Sci Rep, 6, 26800, 10.1038/srep26800 · DOI · Paper page
- Zhang, 2013, Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing, Am J Gastroenterol, 108, 1601, 10.1038/ajg.2013.221 · DOI · Paper page
- Bajaj, 2019, Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis, Clin Gastroenterol Hepatol, 17, 756, 10.1016/j.cgh.2018.07.022 · DOI
- Shen, 2015, Engineering the gut microbiota to treat hyperammonemia, J Clin Invest, 125, 2841, 10.1172/JCI79214 · DOI · Paper page
- Zullo, 2003, Hepatic encephalopathy and Helicobacter pylori: a critical reappraisal, J Clin Gastroenterol, 37, 164, 10.1097/00004836-200308000-00014 · doi:10.1097/00004836-200308000-00014
- Bajaj, 2019, Posttraumatic stress disorder is associated with altered gut microbiota that modulates cognitive performance in veterans with cirrhosis, Am J Physiol Gastrointest Liver Physiol, 317, G661, 10.1152/ajpgi.00194.2019 · DOI
- Nava, 2011, Diversity of the autochthonous colonic microbiota, Gut Microbes, 2, 10.4161/gmic.2.2.15416 · DOI · Paper page
- Wikoff, 2009, Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites, Proc Natl Acad Sci U S A, 106, 3698, 10.1073/pnas.0812874106 · DOI · Paper page
- Bajaj, 2012, A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy, Metab Brain Dis, 27, 205, 10.1007/s11011-012-9303-0 · DOI
- Ridlon, 2016, Consequences of bile salt biotransformations by intestinal bacteria, Gut Microbes, 7, 22, 10.1080/19490976.2015.1127483 · DOI · Paper page
- Nardelli, 2019, Proton pump inhibitors are associated with minimal and overt hepatic encephalopathy and increased mortality in patients with cirrhosis, Hepatology, 70, 640, 10.1002/hep.30304 · DOI · Paper page
- Bajaj, 2018, Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis, Am J Gastroenterol, 113, 1177, 10.1038/s41395-018-0085-9 · DOI
- Sarangi, 2017, Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration, BMC Gastroenterol, 17, 125, 10.1186/s12876-017-0683-9 · DOI
- Wang, 2019, Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: a multicenter, randomized controlled trial, J Dig Dis, 20, 547
- Bass, 2010, Rifaximin treatment in hepatic encephalopathy, N Engl J Med, 362, 1071, 10.1056/NEJMoa0907893 · DOI · Paper page
- Kang, 2016, Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition, Clin Transl Gastroenterol, 7, e187, 10.1038/ctg.2016.44 · DOI
- Wu, 2012, Changes of gut bacteria and immune parameters in liver transplant recipients, Hepatobiliary Pancreat Dis Int, 11, 40, 10.1016/S1499-3872(11)60124-0 · DOI
- Zhang, 2018, Immunosuppressive effect of the gut microbiome altered by high-dose tacrolimus in mice, Am J Transplant, 18, 1646, 10.1111/ajt.14661 · DOI
- Bajaj, 2017, Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis, Liver Transpl, 23, 907, 10.1002/lt.24754 · DOI
- Annavajhala, 2019, Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation, Nat Commun, 10, 4715, 10.1038/s41467-019-12633-4 · DOI
- Bajaj, 2018, Alterations in gut microbial function following liver transplant, Liver Transpl, 24, 752, 10.1002/lt.25046 · DOI
- Bajaj, 2007, Testing for minimal hepatic encephalopathy in the United States: an AASLD survey, Hepatology, 45, 833, 10.1002/hep.21515 · doi:10.1002/hep.21515
- Bajaj, 2019, Specific gut and salivary microbiota patterns are linked with different cognitive testing strategies in minimal hepatic encephalopathy, Am J Gastroenterol, 114, 1080, 10.14309/ajg.0000000000000102 · DOI
- Kamath, 2007, The model for end-stage liver disease (MELD), Hepatology, 45, 797, 10.1002/hep.21563 · DOI · Paper page
- Bajaj, 2018, Fungal dysbiosis in cirrhosis, Gut, 67, 1146, 10.1136/gutjnl-2016-313170 · DOI · Paper page
- Bajaj, 2018, Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis, JCI Insight, 3, 10.1172/jci.insight.98019 · DOI
- Zhang, 2019, Characterization of the circulating microbiome in acute-on-chronic liver failure associated with hepatitis B, Liver Int, 39, 1207, 10.1111/liv.14097 · DOI
- Chen, 2015, Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality, J Gastroenterol Hepatol, 30, 1429, 10.1111/jgh.12932 · DOI · Paper page
- Bajaj, 2019, Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis, Clin Gastroenterol Hepatol, 17, 756, 10.1016/j.cgh.2018.07.022 · DOI
- Duseja, 2019, High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study, BMJ Open Gastroenterol, 6, e000315, 10.1136/bmjgast-2019-000315 · DOI
- Damman, 2018, Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis, Aliment Pharmacol Ther, 47, 886, 10.1111/apt.14540 · DOI
- Eiseman, 1958, Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis, Surgery, 44, 854
- Oren, 2018, Clostridium difficile and Clostridioides difficile: two validly published and correct names, Anaerobe, 52, 125, 10.1016/j.anaerobe.2018.07.005 · DOI
- Kelly, 2008, Clostridium difficile–more difficult than ever, N Engl J Med, 359, 1932, 10.1056/NEJMra0707500 · DOI · Paper page
- Ma, 2017, Increasing incidence of multiply recurrent Clostridium difficile Infection in the United States: a cohort study, Ann Intern Med, 167, 152, 10.7326/M16-2733 · DOI · Paper page
- Bakken, 2011, Treating Clostridium difficile infection with fecal microbiota transplantation, Clin Gastroenterol Hepatol, 9, 1044, 10.1016/j.cgh.2011.08.014 · DOI · Paper page
- Jorgensen, 2019, Banking feces: a new frontier for public blood banks?, Transfusion, 59, 2776, 10.1111/trf.15422 · DOI
- Costello, 2012, The application of ecological theory toward an understanding of the human microbiome, Science, 336, 1255, 10.1126/science.1224203 · DOI · Paper page
- Khoruts, 2015, Development of fecal microbiota transplantation suitable for mainstream medicine, Clin Gastroenterol Hepatol, 13, 246, 10.1016/j.cgh.2014.11.014 · DOI
- Hamilton, 2012, Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection, Am J Gastroenterol, 107, 761, 10.1038/ajg.2011.482 · DOI · Paper page
- Weingarden, 2015, Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection, Microbiome, 3, 10, 10.1186/s40168-015-0070-0 · DOI · Paper page
- Youngster, 2014, Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection, JAMA, 312, 1772, 10.1001/jama.2014.13875 · DOI · Paper page
- Goldenberg, 2018, Comparison of different strategies for providing fecal microbiota transplantation to treat patients with recurrent Clostridium difficile infection in two English hospitals: a review, Infect Dis Ther, 7, 71, 10.1007/s40121-018-0189-y · DOI
- Bajaj, 2017, Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial, Hepatology, 66, 1727, 10.1002/hep.29306 · DOI · Paper page
- Teigen, 2019, Dietary factors in sulfur metabolism and pathogenesis of ulcerative colitis, Nutrients, 11, 10.3390/nu11040931 · DOI
- Martinez-Guryn, 2019, Regional diversity of the gastrointestinal microbiome, Cell Host Microbe, 26, 314, 10.1016/j.chom.2019.08.011 · DOI · Paper page
- Holmes, 2012, Therapeutic modulation of microbiota-host metabolic interactions, Sci Transl Med, 4, 137rv136, 10.1126/scitranslmed.3004244 · DOI · Paper page
- Robertson, 2019, Comparison of co-housing and littermate methods for microbiota standardization in mouse models, Cell Rep, 27, 1910, 10.1016/j.celrep.2019.04.023 · DOI · Paper page
- Costello, 2019, Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial, JAMA, 321, 156, 10.1001/jama.2018.20046 · DOI · Paper page
- Kang, 2017, Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study, Microbiome, 5, 10, 10.1186/s40168-016-0225-7 · DOI · Paper page
- Jalanka, 2016, Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection, BMC Med, 14, 155, 10.1186/s12916-016-0698-z · DOI
- Staley, 2017, Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study, Am J Gastroenterol, 112, 940, 10.1038/ajg.2017.6 · DOI · Paper page
- Staley, 2017, Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota, Gut microbes, 8, 276, 10.1080/19490976.2017.1299310 · DOI
- Staley, 2019, Durable long-term bacterial engraftment following encapsulated fecal microbiota transplantation to treat Clostridium difficile infection, mBio, 10, 10.1128/mBio.01586-19 · DOI
- Manichanh, 2010, Reshaping the gut microbiome with bacterial transplantation and antibiotic intake, Genome Res, 20, 1411, 10.1101/gr.107987.110 · DOI · Paper page
- Vujkovic-Cvijin, 2017, Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals, Gut microbes, 8, 440, 10.1080/19490976.2017.1334034 · DOI
- Jalanka, 2015, Effects of bowel cleansing on the intestinal microbiota, Gut, 64, 1562, 10.1136/gutjnl-2014-307240 · DOI · Paper page
- Comeau, 2007, Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth, PLoS One, 2, e799, 10.1371/journal.pone.0000799 · DOI
- Maiques, 2006, beta-lactam antibiotics induce the SOS response and horizontal transfer of virulence factors in Staphylococcus aureus, J Bacteriol, 188, 2726, 10.1128/JB.188.7.2726-2729.2006 · DOI · Paper page
- Antharam, 2016, An integrated metabolomic and microbiome analysis identified specific gut microbiota associated with fecal cholesterol and coprostanol in Clostridium difficile infection, PLoS One, 11, e0148824, 10.1371/journal.pone.0148824 · DOI
- Nusbaum, 2018, Gut microbial and metabolomic profiles after fecal microbiota transplantation in pediatric ulcerative colitis patients, FEMS Microbiol Ecol, 94, 10.1093/femsec/fiy133 · DOI
- Seekatz, 2018, Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection, Anaerobe, 53, 64, 10.1016/j.anaerobe.2018.04.001 · DOI · Paper page
- Khoruts, 2016, Understanding the mechanisms of faecal microbiota transplantation, Nat Rev Gastroenterol Hepatol, 13, 508, 10.1038/nrgastro.2016.98 · DOI · Paper page
- Staley, 2018, Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation, Microbiome, 6, 166, 10.1186/s40168-018-0549-6 · DOI
- Khanna, 2017, Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease, Microbiome, 5, 55, 10.1186/s40168-017-0269-3 · DOI · Paper page
- Newman, 2017, Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease, Gut microbes, 8, 303, 10.1080/19490976.2017.1279377 · DOI
- Pringle, 2019, Patients with cirrhosis require more fecal microbiota capsules to cure refractory and recurrent Clostridium difficile infections, Clin Gastroenterol Hepatol, 17, 791, 10.1016/j.cgh.2018.05.038 · DOI
- Kao, 2016, Fecal microbiota transplantation in the management of hepatic encephalopathy, Hepatology, 63, 339, 10.1002/hep.28121 · DOI
- Bajaj, 2018, Antibiotic-associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant, Hepatology, 68, 1549, 10.1002/hep.30037 · DOI
- Bajaj, 2019, Long-term outcomes after fecal microbiota transplantation in cirrhosis, Gastroenterology, 156, 1921, 10.1053/j.gastro.2019.01.033 · DOI · Paper page
- Liu, 2020, Neuroinflammation in murine cirrhosis is dependent on the gut microbiome and is attenuated by fecal transplant, Hepatology, 71, 611, 10.1002/hep.30827 · DOI
- Bajaj, 2019, Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial, Hepatology, 70, 1690, 10.1002/hep.30690 · DOI · Paper page
- Bajaj, 2019, Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis, JCI Insight, 4, 10.1172/jci.insight.133410 · DOI
- Kassam, 2019, Donor screening for fecal microbiota transplantation, N Engl J Med, 381, 2070, 10.1056/NEJMc1913670 · DOI
- Ren, 2017, Faecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy, Hepatology, 65, 1765, 10.1002/hep.29008 · DOI · Paper page
- Philips, 2017, Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study, Clin Gastroenterol Hepatol, 15, 600, 10.1016/j.cgh.2016.10.029 · DOI · Paper page
- Philips, 2018, Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis, Indian J Gastroenterol, 37, 215, 10.1007/s12664-018-0859-4 · DOI
- Djulbegovic, 2011, Uncertainty and equipoise: at interplay between epistemology, decision making and ethics, Am J Med Sci, 342, 282, 10.1097/MAJ.0b013e318227e0b8 · DOI
- Kakiyama, 2013, Modulation of the fecal bile acid profile by gut microbiota in cirrhosis, J Hepatol, 58, 949, 10.1016/j.jhep.2013.01.003 · DOI · Paper page
- Cox, 2020, Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis, Liver Int, 40, 416, 10.1111/liv.14256 · DOI
- Tuomisto, 2014, Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics, BMC Gastroenterol, 14, 40, 10.1186/1471-230X-14-40 · DOI
- Bajaj, 2015, Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus, Sci Rep, 5, 18559, 10.1038/srep18559 · DOI
- Santiago, 2016, Alteration of the serum microbiome composition in cirrhotic patients with ascites, Sci Rep, 6, 25001, 10.1038/srep25001 · DOI
- Iebba, 2018, Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy, Sci Rep, 8, 8210, 10.1038/s41598-018-26509-y · DOI
- Jacobs, 2018, Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: the microbiome, microbial markers and liver disease study, Hepatol Res, 48, 1108, 10.1111/hepr.13207 · DOI
- Schierwagen, 2019, Circulating microbiome in blood of different circulatory compartments, Gut, 68, 578, 10.1136/gutjnl-2018-316227 · DOI
- Raj, 2019, Dysbiosis of the duodenal mucosal microbiota is associated with increased small intestinal permeability in chronic liver disease, Clin Transl Gastroenterol, 10, e00068, 10.14309/ctg.0000000000000068 · DOI
- Bajaj, 2019, Alterations in skin microbiomes of patients with cirrhosis, Clin Gastroenterol Hepatol, 17, 2581, 10.1016/j.cgh.2019.03.028 · DOI
- Chen, 2015, Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality, J Gastroenterol Hepatol, 30, 1429, 10.1111/jgh.12932 · DOI · Paper page
- Ahluwalia, 2012, Rifaximin improves brain edema and working memory in minimal hepatic encephalopathy: a prospective fMRI study, Hepatology, 56, 162A
- Kaji, 2017, Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity, World J Gastroenterol, 23, 8355, 10.3748/wjg.v23.i47.8355 · DOI
- Schulz, 2019, Long-term effect of rifaximin with and without lactulose on the active bacterial assemblages in the proximal small bowel and faeces in patients with minimal hepatic encephalopathy, Dig Dis, 37, 161, 10.1159/000494216 · doi:10.1159/000494216
- Horvath, 2019, Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis, Sci Rep, 9, 12000, 10.1038/s41598-019-48352-5 · DOI · Paper page
- Bajaj, 2014, Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis, Aliment Pharmacol Ther, 39, 1113, 10.1111/apt.12695 · DOI · Paper page
- Xia, 2018, Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis, J Int Med Res, 46, 3596
- Acharya, 2017, Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis, Aliment Pharmacol Ther, 45, 319, 10.1111/apt.13858 · DOI · Paper page
- Bajaj, 2018, Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis, Am J Physiol Gastrointest Liver Physiol, 315, G824, 10.1152/ajpgi.00230.2018 · DOI
- Bajaj, 2017, Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial, Hepatology, 66, 1727, 10.1002/hep.29306 · DOI · Paper page
- Bajaj, 2019, Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis, Gastroenterology, 156, 1921, 10.1053/j.gastro.2019.01.033 · DOI · Paper page
- Mehta, 2018, Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-A case series, Indian J Gastroenterol, 37, 559, 10.1007/s12664-018-0906-1 · DOI
Cited by
Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders
Chopyk, D. M., & Grakoui, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.077 · Cited by 490
Gut microbiome, liver immunology, and liver diseases
Wang, R., Tang, R., Li, B., Ma, X., Schnabl, B., & Tilg, H. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00592-6 · Cited by 466
The microbiota in cirrhosis and its role in hepatic decompensation
Trebicka, J., Macnaughtan, J., Schnabl, B., Shawcross, D. L., & Bajaj, J. S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.013 · Cited by 268
Self-citationLee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004779 · Cited by 217
Promises of microbiome-based therapies
Bajaj, J. S., Ng, S. C., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.003 · Cited by 119
Self-citation
Metadata
- Authors
- Bajaj, J. S., & Khoruts, A.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 72
- Issue
- 5
- Pages
- 1003-1027
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3003277102
- Cited by
- 167
- References
- 48
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Center for Advancing Translational Sciences
- Agency for Healthcare Research and Quality
- VHA Office of Research and Development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.